The renin angiotensin system (RAS) plays an important role in the pathogenesis of variety of diseases. Targeting the formation and action of angiotensin II (Ang II), the main RAS peptide, has been the key therapeutic target for last three decades. ACE‐related carboxypeptidase (ACE2), a monocarboxypeptidase that had been discovered 20 years ago, is one of the catalytically most potent enzymes known to degrade Ang II to Ang‐(1‐7), a peptide that is increasingly accepted to have organ‐protective properties that oppose and counterbalance those of Ang II. In addition to its role as a RAS enzyme ACE2 is the main receptor for SARS‐CoV‐2. In this review, we discuss various strategies that have been used to achieve amplification of ACE2 activity including the potential therapeutic potential of soluble recombinant ACE2 protein and novel shorter ACE2 variants.

中文翻译：

---

ACE2 扩增及其治疗潜力的最新进展。

肾素血管紧张素系统（RAS）在多种疾病的发病机制中起重要作用。针对主要 RAS 肽血管紧张素 II (Ang II) 的形成和作用，在过去三十年中一直是关键的治疗靶点。ACE 相关羧肽酶 (ACE2) 是 20 年前发现的一种单羧肽酶，是已知的催化最有效的酶之一，可将 Ang II 降解为 Ang-(1-7)，这种肽越来越被认为具有器官-对抗和抵消 Ang II 的保护特性。除了作为 RAS 酶的作用外，ACE2 还是 SARS-CoV-2 的主要受体。在本次审查中，